27 January 2022  
EMA/CHMP/40668/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Ayvakyt 
avapritinib 
On 27 January 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Ayvakyt. The marketing authorisation holder for this medicinal product is Blueprint Medicines 
(Netherlands) B.V. 
The CHMP adopted two new strengths, 25 mg and 50mg film coated tablets, and a new indication as 
follows:2 
Unresectable or metastatic gastrointestinal stromal tumour (GIST) 
AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or 
metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor 
receptor alpha (PDGFRA) D842V mutation. 
Advanced systemic mastocytosis (AdvSM) 
AYVAKYT is indicated as monotherapy for the treatment of adult patients with 
aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated 
haematological neoplasm (SM-AHN) or mast cell leukaemia (MCL), after at least one 
systemic therapy. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR), and will be available in all official European Union languages after a decision on this change to 
the marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text as bold. 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
